Analgesic Nephropathy — A Preventable Renal Disease

New England Journal of Medicine

Volumn 320, Issue 19, 1989, Pages 1269-1271

  Bennett, William M ^a   Debroe, Marc E ^b  

^a UNIVERSITY OF PORTLAND   (United States)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; IBUPROFEN; PARACETAMOL; PHENACETIN;

ANALGESIC NEPHROPATHY; CHRONIC KIDNEY DISEASE; EDITORIAL; HUMAN; PRIORITY JOURNAL;

EID: 0024517966     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198905113201908     Document Type: Editorial

References (20)

1. Physicians' desk reference. Oradell, N.J.: Medical Economics, 1989.
2. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989; 320: 1238–43.
3. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983; 143: 1687–93.
4. Segasothy M, Suleiman AB, Puvaneswary M, Rohana A. Paracetamol: a cause for analgesic nephropathy and end-stage renal disease. Nephron 1988; 50: 50–4.
5. Pommer W, Bronder E, Greiser E, et al. Regular analgesic intake and the risk of end stage renal failure. Am J Nephrol (in press).
6. Kincaid-Smith P. Analgesic abuse and the kidney. Kidney Int 1980; 17: 250–60.
7. McCredie M, Stewart JH, Carter JJ, Turner J, Mahoney JF. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int 1986; 30: 81–4.
8. McCredie M, Stewart JH. Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron 1988; 49: 296–300.
9. Walker RJ, Duggin GG. Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 1988; 28: 331–45.
10. Brezis M, Rosen S, Epstein FH. The pathophysiological implications of medullary hypoxia. Am J Kidney Dis 1989; 13: 253–8.
11. Pommer W, Glaeske G, Molzahn M. The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin Nephrol 1986; 26: 273–8.
12. Disney AP, ed. Eleventh report of the Australia and New Zealand combined dialysis and transplant registry. Woodville, South Australia: Queen Elizabeth Hospital, 1988.
13. Elseviers MM, DeBroe ME. Is analgesic nephropathy still a problem in Belgium? Nephrol Dial Transplant 1988; 2: 143–9.
14. Ad Hoc Committee for the National Kidney Foundation. Statement on the release of ibuprofen as an over-the-counter medicine. Am J Kidney Dis 1985; 6: 4–6.
15. Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Adu D. Nonsteroidal anti-inflammatory drugs and renal failure. Lancet 1986; 1: 57–60.
16. Champion de Crespigny PJ, Hewitson T, Birchall I, Kincaid-Smith P. Caffeine potentiates the nephrotoxicity of mefenamic acid on the rat renal papilla. Nephron (in press).
17. Analgesic-associated kidney disease. JAMA 1984; 251: 3123–5.
18. Prescott LF. Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics. Drugs 1982; 23: 75–149.
19. Nanra RS, Kincaid-Smith P. Renal papillary necrosis in rheumatoid arthritis. Med J Aust 1975; 1: 194–7.
20. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin: renal morbidity and mortality (1968–1979). N Engl J Med 1983; 308: 357–62.